Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia
Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia
Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia Supraventricular tachycardia (SVT) is a rapid heart rhythm that originates above the ventricles, often causing episodes of palpitations, dizziness, or chest discomfort. It is a common arrhythmia seen in both outpatient and emergency settings. Managing SVT effectively requires a clear understanding of its mechanisms and the appropriate interventions, among which adenosine plays a crucial role.
Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia Adenosine is a naturally occurring nucleoside in the body that exerts significant effects on the heart’s conduction system. It primarily acts on the A1 receptors in the atrioventricular (AV) node, leading to transient conduction blockade. This property makes adenosine especially useful in diagnosing and terminating certain types of SVT, particularly AV nodal reentrant tachycardia (AVNRT) and AV reciprocating tachycardia (AVRT).
In clinical practice, adenosine is administered intravenously during episodes of SVT to achieve rapid termination of the arrhythmia. Its onset of action is remarkably quick—often within seconds—making it an ideal agent for acute intervention. The typical dose begins with a rapid IV bolus of 6 mg, followed by a saline flush. If the initial dose fails to terminate the tachycardia within a few minutes, a second dose of 12 mg may be administered. In some cases, a third dose can be given if necessary.
One of the key advantages of adenosine is its short half-life, approximately 10 seconds, which means any adverse effects are usually brief. During administration, patients may experience sensations such as chest discomfort, flushing, or a sense of impending doom. These side effects are transient, and serious adverse effects are rare but can include bronchospasm or transient atrioventricular block. Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia
The use of adenosine is generally safe in patients without contraindications. Caution should be exercised in individuals with asthma or bronchospastic disease due to potential bronchoconstriction. It is also contraindicated in patients with certain types of heart block or sick sinus syndrome unless a pacemaker is in place. Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia
Beyond its role in terminating SVT, adenosine has diagnostic utility. When administered, it can transiently block AV conduction, revealing underlying atrial activity and helping distinguish SVT from other arrhythmias such as atrial flutter or fibrillation. This diagnostic capability can guide further management decisions. Adenosine and supraventricular tachycardia Adenosine and supraventricular tachycardia
While adenosine is highly effective, it is not suitable for all types of tachycardia. In cases where adenosine fails, or in arrhythmias originating from the atria or ventricles that do not involve AV nodal reentry, alternative treatments such as beta-blockers, calcium channel blockers, or cardioversion may be necessary.
In conclusion, adenosine remains a cornerstone in the acute management of SVT due to its rapid action, high efficacy, and diagnostic utility. Proper understanding of its pharmacology, administration, and contraindications ensures safe and effective treatment, significantly improving patient outcomes during episodes of these often distressing arrhythmias.
